Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 19, 2007

View Archived Issues

SONOMA-2 shows effect of alfimeprase on occluded central venous access devices

New agents for autoimmune disorders and transplant rejection imparted in recent patent literature

Recent patents disclose new therapeutic agents for HBV and HCV infection

DuoCort completes enrollment in phase II/III clinical trial of DuoCort for adrenal insufficiency

Genmab to initiate phase II trial of ofatumumab for relapsing-remitting multiple sclerosis

BioCancell submits IND application to the FDA for BC-819 in bladder cancer

LOTS study of Genzyme's Myozyme for Pompe disease meets coprimary efficacy endpoints

BioMimetic reports positive clinical results for GEM-OS1 for foot and ankle fusion

The CHMP of the EMEA issues negative opinion on Pharming's MAA for Rhucin

Novel therapeutic agents for respiratory disorders disclosed in recent patents

GSK launches ArranonG in Japan for leukemia and malignant lymphoma

FDA grants fast track designation to Neurologix's gene therapy approach to Parkinson's disease

Novelos Therapeutics concludes phase Ib trial of NOV-205 for hepatitis C genotype 1

Increased survival in mouse models of multiple myeloma with Prolexys' new compound

Dual Akt/p70S6K inhibitor effective against multiple myeloma in vitro

DCC-2036 shows preclinical antileukemic activity against drug-resistant CML

Data safety monitoring board recommends continuation of two phase III trials of Hemospan

European Commission grants marketing authorization for Atripla for HIV-1

Vasogen and Ferrer begin roll-out of Celacade for heart failure therapy

Careload LA, a pulmonary arterial hypertension agent, launched in Japan

Takeda submits indication extension application for Basen in Japan

FDA approves supplemental indication for Genzyme's Thyrogen in thyroid cancer ablation

Avastin approved in Europe for first-line treatment of advanced RCC

Cell Therapeutics to submit MAA for Xyotax in the first quarter of 2008 ahead of schedule

FDA approves beta-blocker Bystolic for the treatment of hypertension

Philippine Bureau of Food and Drugs grants product registration for Epeius' Rexin-G

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.